Combination drug release of smart cyclodextrin-gated mesoporous silica nanovehicles

2015 ◽  
Vol 51 (33) ◽  
pp. 7203-7206 ◽  
Author(s):  
Shengwang Zhou ◽  
Huizi Sha ◽  
Xiaokang Ke ◽  
Baorui Liu ◽  
Xizhang Wang ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Drug Release ◽  
Mesoporous Silica ◽  
Delivery System ◽  
Drug Loading ◽  
Combination Drug Therapy ◽  
Combination Drug ◽  
Covalent Bonds ◽  
Dual Drug

A smart γ-cyclodextrin-gated mesoporous silica delivery system with dual drug loading was constructed via dual dynamic covalent bonds in combination drug therapy.

Development of a dual drug-loaded hydrogel delivery system for enhanced cancer therapy: in situ formation, degradation and synergistic antitumor efficiency

2017 ◽  
Vol 5 (43) ◽  
pp. 8487-8497 ◽  
Author(s):  
Cui Cheng ◽  
Xiuli Zhang ◽  
Yabin Meng ◽  
Li Chen ◽  
Qiqing Zhang
Keyword(s):  
Drug Therapy ◽  
Cancer Therapy ◽  
Delivery System ◽  
Combination Drug Therapy ◽  
Stimuli Responsive ◽  
Combination Drug ◽  
In Situ Formation ◽  
Dual Drug

A stimuli-responsive, biodegradable, and dual drug-loaded hydrogel delivery system was formed in situ for combination drug therapy of cancer in vivo.

scholarly journals Nanomedicine-Mediated Combination Drug Therapy in Tumor

2017 ◽  
Vol 4 (1) ◽  
pp. 1-10 ◽  
Author(s):  
Dazhong Chen ◽  
Fangyuan Xie ◽  
Duxin Sun ◽  
Chuan Yin ◽  
Jie Gao ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Polymeric Micelles ◽  
Drug Loading ◽  
Drug Uptake ◽  
Hybrid Nanoparticles ◽  
Multiple Drug ◽  
Combined Chemotherapy ◽  
Combination Drug Therapy ◽  
Combination Drug

Background:Combined chemotherapy has gradually become one of the conventional methods of cancer treatment due to the limitation of monotherapy. However, combined chemotherapy has several drawbacks that may lead to treatment failure because drug synergy cannot be guaranteed, achievement of the optimal synergistic drug ratio is difficult, and drug uptake into the tumor is inconsistent. Nanomedicine can be a safe and effective form of drug delivery, which may address the problems associated with combination chemotherapy.Objective:This review summarizes the recent research in this area, including the use of nanoparticles, liposomes, lipid-polymer hybrid nanoparticles, and polymeric micelles, and provides new approach for combined chemotherapy.Methods:By collecting and referring to the related literature in recent years.Results:Compared with conventional drugs, nanomedicine has the following advantages: it increases bioavailability of poorly soluble drugs, prolongs drug circulation timein vivo, and permits multiple drug loading, all of which could improve drug efficacy and reduce toxicity. Furthermore, nanomedicine can maintain the synergistic ratio of the drugs; deliver the drugs to the tumor at the same time, such that two or more drugs of tumor treatment achieve synchronization in time and space; and alter the pharmacokinetics and distribution profilein vivosuch that these are dependent on nanocarrier properties (rather than being dependent on the drugs themselves).Conclusion:Therefore, nanomedicine-mediated combination drug therapy is promising in the treatment of tumors.

Study of pH-Responsive and Polyethylene Glycol-Modified Doxorubicin-Loaded Mesoporous Silica Nanoparticles for Drug Delivery

2020 ◽  
Vol 20 (10) ◽  
pp. 5997-6006
Author(s):  
Yujie Qin ◽  
Xiaoqian Shan ◽  
Yu Han ◽  
Hang Jin ◽  
Ying Gao
Keyword(s):  
Drug Delivery ◽  
Polyethylene Glycol ◽  
Drug Release ◽  
Mesoporous Silica ◽  
Drug Delivery System ◽  
Delivery System ◽  
Phosphate Buffer ◽  
Drug Loading ◽  
Phosphate Buffer Solution ◽  
Tumor Cell Death

Tumor-targeted drug delivery systems represent challenging and widely investigated strategies to enhance cancer chemotherapy. In this study, we introduce a novel high-hydrophilic mesoporous silica nanoparticle system with a pH-sensitive drug release. The resultant composite nanoparticles appear as spheres of uniform size (450±25 nm) with a porous structure, which enables a high drug-loading ratio. Through modification of chitosan and polyethylene glycol monomethyl ether, the modified mesoporous silica was non-toxic to normal cells, but effective at inducing tumor cell death. With regard to the characteristics of drug release, the modified mesoporous silica clearly displayed a pH-stimulated release of the model drug doxorubicin hydrochloride in an acidic phosphate buffer solution (pH 4.0 and 6.0). The release was much greater than that observed in neutral or alkaline phosphate buffer solutions (pH 7.3 and 8.0). Furthermore, the release behavior was in accordance with the Higuchi model, indicating that this modified mesoporous silica drug delivery system can exhibit controlled release. The above results imply that the modified mesoporous silica is an effective drug delivery system for cancer therapy.

pH-Sensitive Drug Delivery System Based on Mesoporous Silica Modified with Poly-L-Lysine (PLL) as a Gatekeeper

2020 ◽  
Vol 20 (11) ◽  
pp. 6925-6934
Author(s):  
Nam-Kyoung Lee ◽  
Sung Soo Park ◽  
Chang-Sik Ha
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Mesoporous Silica ◽  
Drug Delivery System ◽  
Delivery System ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Loading ◽  
Acidic Condition ◽  
Cargo Transport ◽  
Environmental Trigger

In this work, we synthesized a novel pH-triggered drug delivery system to enhance the bioavailability of the anticancer drug doxorubicin (DOX) through the gatekeeper poly-L-lysine (PLL) on the pore entrances of mesoporous silica nanoparticles (MSNs). Firstly, mesoporous silica was selected as the inorganic support for drug loading. Secondly, PLL was employed as the gatekeeper to control the cargo transport. In a neutral environment, the PLL brushes became shrunken and formed a dense barrier on the pore entrances of PLL/MSNs, which closed the pores and thus prevented the release of cargo. In an acidic environment, the cargo was released from the carrier PLL/MSNs because the pore entrances were opened by the swollen PLL brushes. The DOX-loaded PLL/MSNs (PLL/MSNs-DOX) showed 1.5 times higher drug release under acidic condition (pH = 4) than under neutral condition (pH = 7). During the drug release experiment for 48 h under acidic condition, PLL/MSN-DOX released about 50% of the drug after 9 h and approximately 85% after 24 h, whereas pristine MSNs loaded with DOX (MSNs-DOX) released about 50% of the drug after 30 min and reached equilibrium after 24 h. The MSNs also demonstrated their effectiveness in storing anticancer drugs until the desired environmental trigger is present. Therefore, the pH-responsive MSNs have great potential as a targeting cancer therapy.

scholarly journals Polymeric Mesoporous Silica Nanoparticles for Combination Drug Delivery In vitro

2020 ◽  
Vol 11 (4) ◽  
pp. 11905-11919
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Mesoporous Silica ◽  
Anticancer Activity ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Formulation ◽  
Combination Drug ◽  
Dual Drug

Despite the recent advances and development of conventional cancer therapy strategies, treatments often lack specificity, resulting in low therapeutic efficiency, cancer recurrence, and drug resistance. With the advent of nanotechnology, nanoparticle-based delivery systems have steadily gained interest. The key to using any drug delivery system is its’ relative cytotoxicity, pharmacokinetics, and downstream immunological effects that may arise upon repetitive exposure. Among the nanoparticle systems, mesoporous silica nanoparticles (MSNs) have received favorable attention as potential drug delivery platforms. This study aimed to synthesize and functionalized MSNs with chitosan and polyethyleneglycol for improved stability, efficient drug loading, and drug release. These polymerized MSNs were physicochemically and morphologically characterized and assessed for their dual-drug [doxorubicin (DOX)/5-fluoruracil (5-FU)] loading, drug release kinetics, and anticancer activity in vitro. MSNs ranged from 35-70 nm in size, with a high surface area (809.44 m²/g) and a large pore volume (1.74 cm²/g). The DOX/5-FU co-loading produced a potent dual-drug formulation with good pH-responsive release profiles, high percentage release, especially from PEGylated MSNs, and significant anticancer activity the breast adenocarcinoma (MCF-7) and cervical cancer (HeLa) cells. This combination therapy's favorable outcomes suggest an improved therapeutic strategy that warrants investigation in an in vivo model.

scholarly journals Formulation and Optimization of Pulsatile Tablet for Circadian Rhythm of Blood Pressure

2020 ◽  
pp. 204-219
Keyword(s):  
Blood Pressure ◽  
Circadian Rhythm ◽  
Drug Therapy ◽  
Drug Release ◽  
Lag Time ◽  
The Body ◽  
Oral Drug ◽  
Plasma Norepinephrine ◽  
Combination Drug Therapy ◽  
Combination Drug

Circadian rhythm is a 24-hour cycle of human body, the body different aspect in the morning as compare to afternoon or night. The blood pressure rises in two time in a day, one is at early morning and second one is at evening.The aim of present project work was to design the pulsatile tablet for treatment of blood pressure with combination drug therapy. in most cases it is seen that the increasing in Plasma norepinephrine level and plasma renin activity in the morning; both hormones are potential to induce coronary vasoconstriction, therefore, there is a need to a such formulation who achieve peak plasma concentration of drug at morning and can control morning spate of B.P. The pulsatile release of nebivolol after the lag time with sustain release of curcumin which maintain the severity of blood Pressure. The Formulation of Core tablet of nebivolol was prepared by using superdisintegrate by direct compression with diluent. F10 batch was found to be optimized formulation as it shown potent drug release within short time. The lag time was prolonged with an increase of the coating level, whereas the drug release rate was almost constant, irrespective of the coating level the lag time of nebivolol was found to be 8 to 8.5hrsand drug release after 9hrs. drug release was above 95% after lag time with constant release of curcumin. Hence, this approach can provide a useful means and may be helpful for patients with morning spate of BP and development of PDDS of combination drug therapy is a promising approach to overcome the side effect of single drug i.e. nebivolol drug therapy and also oral drug delivery.

Mesoporous Silica Molecular Sieve based Nanocarriers: Transpiring Drug Dissolution Research

2017 ◽  
Vol 23 (3) ◽  
pp. 467-480 ◽  
Author(s):  
Satyanarayan Pattnaik ◽  
Kamla Pathak
Keyword(s):  
Drug Release ◽  
Mesoporous Silica ◽  
Molecular Sieves ◽  
Release Kinetics ◽  
Drug Loading ◽  
Scale Up ◽  
Water Soluble ◽  
Drug Dissolution ◽  
Water Soluble Drugs ◽  
Loading Methods

Background: Improvement of oral bioavailability through enhancement of dissolution for poorly soluble drugs has been a very promising approach. Recently, mesoporous silica based molecular sieves have demonstrated excellent properties to enhance the dissolution velocity of poorly water-soluble drugs. Description: Current research in this area is focused on investigating the factors influencing the drug release from these carriers, the kinetics of drug release and manufacturing approaches to scale-up production for commercial manufacture. Conclusion: This comprehensive review provides an overview of different methods adopted for synthesis of mesoporous materials, influence of processing factors on properties of these materials and drug loading methods. The drug release kinetics from mesoporous silica systems, the manufacturability and stability of these formulations are reviewed. Finally, the safety and biocompatibility issues related to these silica based materials are discussed.

Combination drug therapy for dyslipidemia

1999 ◽  
Vol 1 (1) ◽  
pp. 44-49 ◽  
Author(s):  
Khaldoon Alaswad ◽  
James H. O’Keefe ◽  
Richard M. Moe
Keyword(s):  
Drug Therapy ◽  
Combination Drug Therapy ◽  
Combination Drug
Sign in / Sign up

Export Citation Format

Share Document